|
 |
| home > ebr > spring 2004 > reviews recent bse concerns and the relevance of clearance studies |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
The announcement that bovine spongiform encephalopathy (BSE) was found in one cow located in the state of Washington in the US caused quite a furore (1). Some countries went so far as to propose banning all US-made health care products. Immediately, sponsors who knowingly used serum produced from US cows began to assess their need to perform transmissible spongiform encephalopathy (TSE) clearance studies. Others began frantically searching archived records to determine if their products had ever been in contact with US bovine products. Many began immediate planning for TSE clearance studies.
A risk assessment may show that extensive clearance studies are in fact not needed. It is essential to address the current concerns related to one US case of BSE in a rational fashion. A risk assessment that includes consideration of relevant safety issues can provide insight into the most appropriate approach to a timely and cost-effective solution. Consideration of the following questions may be useful in such a risk assessment:
What is the risk of the product transmitting BSE to humans?
Are there already appropriate controls and methods in place that eliminate theoretical risks?
What are the current regulatory expectations?
If a clearance evaluation study is appropriate, what are the issues that must be considered? |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Small Scale Biomanufacturing – clinical trials, cell & gene therapies
18 September 2008, Clifton Pavilion, Bristol Zoo Gardens, Bristol
This one day conference, sponsored by bioProcessUK and organised by BioApproaches South West, will cover key, important topics relating to small scale GMP biomanufacturing.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
